Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
Holding RPHM?
Track your performance easily
RPHM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $9.21
Previous Close$1.37
Volume234.76K
Average Volume (3M)134.24K
Market Cap
$45.80M
Enterprise Value-$30.05M
Total Cash (Recent Filing)$76.67M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 06, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding33,428,808
10 Day Avg. Volume153,559
30 Day Avg. Volume134,239
Standard Deviation0.30
R-Squared0.00109
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Reneo Pharmaceuticals News
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Executive Departure
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Merger and Strategic PIPE Investment
Bulls Say, Bears Say
Bulls Say
Financing$65M private investment in public equity (PIPE) financing expected to close with the merger.
LeadershipOnKure leadership has a high-quality pedigree in oncology.
MergerMerger with OnKure pivots story towards oncology.
Bears Say
Financial PerformanceRPHM reported a 1Q24 net loss of $8.4M, or ($0.25) per share.
Operational ChangesThe company implemented cost saving initiatives, including suspension of all mavodelpar development activities and a reduction in force of approximately 90%.
Product DevelopmentThe company suspended mavodelpar development after the pivotal Phase 2b STRIDE study did not meet either primary or secondary efficacy endpoint in primary mitochondrial myopathies.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RPHM FAQ
What was Reneo Pharmaceuticals’s price range in the past 12 months?
Reneo Pharmaceuticals lowest stock price was $0.98 and its highest was $9.21 in the past 12 months.
What is Reneo Pharmaceuticals’s market cap?
Currently, no data Available
When is Reneo Pharmaceuticals’s upcoming earnings report date?
Reneo Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Reneo Pharmaceuticals’s earnings last quarter?
Reneo Pharmaceuticals released its earnings results on Aug 13, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.06.
Is Reneo Pharmaceuticals overvalued?
According to Wall Street analysts Reneo Pharmaceuticals’s price is currently Overvalued.
Does Reneo Pharmaceuticals pay dividends?
Reneo Pharmaceuticals does not currently pay dividends.
What is Reneo Pharmaceuticals’s EPS estimate?
Reneo Pharmaceuticals’s EPS estimate is -$0.07.
How many shares outstanding does Reneo Pharmaceuticals have?
Reneo Pharmaceuticals has 33,428,806 shares outstanding.
What happened to Reneo Pharmaceuticals’s price movement after its last earnings report?
Reneo Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went up 2.985%.
Which hedge fund is a major shareholder of Reneo Pharmaceuticals?
Among the largest hedge funds holding Reneo Pharmaceuticals’s share is Highbridge Capital Management LLC. It holds Reneo Pharmaceuticals’s shares valued at 4M.
---
Reneo Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
RPHM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 178.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $863.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.30%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-46.83%
Trailing 12-Months
Company Description
Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
RPHM Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Foghorn Therapeutics
―
Heron Therapeutics
―
Seres Therapeutics
―
Praxis Precision Medicines
―
Best Analysts Covering RPHM
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-36.85%
reiterated a sell rating 6 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -36.85% per trade.
---